Impax Labs, retailers ink midtrial settlement in Solodyn 'pay-for-delay' case

contract
Impax agreed to settle with a group of retailers in Solodyn antitrust litigation. (Pixabay)

In pharma's second "pay-for-delay" settlement in under a week, a class of retailers have dropped claims that Impax Labs made an illegal deal to delay the launch of its generic version of Valeant's acne drug Solodyn. 

The agreement with retailers such as Walgreens, Kroger and CVS stipulates that each side will pay its own legal fees, a court filing stated; other terms weren't disclosed. A spokesperson for Impax didn't immediately respond to a request for comment.

This week's development follows another settlement inked by Impax earlier this month—worth $35 million—with direct purchasers, according to court filings. Valeant, which acquired Solodyn in its 2012 Medicis buyout, last month disclosed its own $58 million settlement related to the allegations.

Webinar

Striving for Zero in Quality & Manufacturing

Pharmaceutical and medical device manufacturers strive towards a culture of zero – zero hazards, zero defects, and zero waste. This on-demand webinar discusses the role that content management plays in pharmaceutical manufacturing to help companies reach the goal of zero in Quality and Manufacturing.

Despite the settlements, the Solodyn litigation still includes claims by insurers and consumers, Reuters notes. The case has been at trial since mid-March, according to the court. 

The lawsuit claims Solodyn manufacturer Medicis and Impax violated antitrust laws with a 2008 pay-for-delay deal. Medicis forked over $40 million, plus more in "milestones," to Impax, which in return dropped a patent lawsuit and delayed its generic entrant, the lawsuit says. Impax has denied wrongdoing, according to Reuters. 

RELATED: Endo, Teva join $270M deal to wrap up Lidoderm pay-for-delay lawsuit 

So-called pay-for-delay deals have long irked federal officials and lawmakers, and the FTC has been working to get tough on them in recent years. In 2013, the Supreme Court ruled that the deals aren't always lawful, undercutting a defense by drugmakers that they are legal. 

Impax's deal follows a settlement last week by Endo, Teva and Japan's Teikoku Seiyaku to wrap up pay-for-delay claims over generic Lidoderm. That arrangement is worth $270 million.

RELATED: Bisaro steers Impax to $6.4B Amneal merger, creating fifth-largest U.S. generics company 

Meanwhile, Impax is working to merge with Amneal in response to intense pricing pressure that's weighing on the generic industry. The company appointed former Actavis CEO as its helmsman last March and in October agreed to the $6.4 billion Amneal merger. Now, the drugmaker says it's on track to close the deal in the second quarter of this year. 

Suggested Articles

Alnylam is ready to follow on its Onpattro launch with an FDA nod for Givlaari. But the drug's safety profile is giving analysts reason to pause.

FDA nominee Stephen Hahn faced questions from Senators on Wednesday on topics including drug pricing, biosimilars, opioids and more.

BMS’ Opdivo-Yervoy combo been game-changing in late-stage melanoma. But when it comes to expanding the pair’s reach, the company has hit a roadblock.